» Articles » PMID: 25705881

X-linked Macrocytic Dyserythropoietic Anemia in Females with an ALAS2 Mutation

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2015 Feb 24
PMID 25705881
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Macrocytic anemia with abnormal erythropoiesis is a common feature of megaloblastic anemias, congenital dyserythropoietic anemias, and myelodysplastic syndromes. Here, we characterized a family with multiple female individuals who have macrocytic anemia. The proband was noted to have dyserythropoiesis and iron overload. After an extensive diagnostic evaluation that did not provide insight into the cause of the disease, whole-exome sequencing of multiple family members revealed the presence of a mutation in the X chromosomal gene ALAS2, which encodes 5'-aminolevulinate synthase 2, in the affected females. We determined that this mutation (Y365C) impairs binding of the essential cofactor pyridoxal 5'-phosphate to ALAS2, resulting in destabilization of the enzyme and consequent loss of function. X inactivation was not highly skewed in wbc from the affected individuals. In contrast, and consistent with the severity of the ALAS2 mutation, there was a complete skewing toward expression of the WT allele in mRNA from reticulocytes that could be recapitulated in primary erythroid cultures. Together, the results of the X inactivation and mRNA studies illustrate how this X-linked dominant mutation in ALAS2 can perturb normal erythropoiesis through cell-nonautonomous effects. Moreover, our findings highlight the value of whole-exome sequencing in diagnostically challenging cases for the identification of disease etiology and extension of the known phenotypic spectrum of disease.

Citing Articles

Three-generation female cohort with macrocytic anemia and iron overload.

Boucher A, Dayton V, Pratt A, Nassar N, Elgammal Y, Kalfa T Am J Hematol. 2024; 100(1):133-138.

PMID: 39329459 PMC: 11625981. DOI: 10.1002/ajh.27489.


Iron metabolism, ferroptosis, and lncRNA in cancer: knowns and unknowns.

Qu L, He X, Tang Q, Fan X, Liu J, Lin A J Zhejiang Univ Sci B. 2022; 23(10):844-862.

PMID: 36226538 PMC: 9561407. DOI: 10.1631/jzus.B2200194.


Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosis.

Ono K, Fujiwara T, Saito K, Nishizawa H, Takahashi N, Suzuki C Sci Rep. 2022; 12(1):9024.

PMID: 35637209 PMC: 9151922. DOI: 10.1038/s41598-022-12940-9.


Identification of Regulatory Factors and Prognostic Markers in Amyotrophic Lateral Sclerosis.

Sun H, Li M, Ji Y, Zhu J, Chen Z, Zhang L Antioxidants (Basel). 2022; 11(2).

PMID: 35204186 PMC: 8868268. DOI: 10.3390/antiox11020303.


X-linked sideroblastic anaemia in a female fetus: a case report and a literature review.

Nzelu D, Shangaris P, Story L, Smith F, Piyasena C, Alamelu J BMC Med Genomics. 2021; 14(1):296.

PMID: 34930268 PMC: 8686580. DOI: 10.1186/s12920-021-01146-z.


References
1.
Cotter P, Baumann M, Bishop D . Enzymatic defect in "X-linked" sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci U S A. 1992; 89(9):4028-32. PMC: 525625. DOI: 10.1073/pnas.89.9.4028. View

2.
Cazzola M, May A, Bergamaschi G, Cerani P, Rosti V, Bishop D . Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood. 2000; 96(13):4363-5. View

3.
Bottomley S, May B, Cox T, Cotter P, Bishop D . Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia. J Bioenerg Biomembr. 1995; 27(2):161-8. DOI: 10.1007/BF02110031. View

4.
Davenport J . Macrocytic anemia. Am Fam Physician. 1996; 53(1):155-62. View

5.
Hoffbrand V, Provan D . ABC of clinical haematology. Macrocytic anaemias. BMJ. 1997; 314(7078):430-3. PMC: 2125890. DOI: 10.1136/bmj.314.7078.430. View